Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 20, 2009

Ferring Approved to Commercialize Prostate Cancer Drug within EU

Ferring Approved to Commercialize Prostate Cancer Drug within EU

Ferring will commercialize Firmagon in EU

  • Ferring Pharmaceuticals received authorization from the European Commission to market Firmagon, a prostate cancer drug. The treatment is a gonadotropin-releasing hormone receptor antagonist, indicated for patients with advanced, hormone-dependent prostate cancer. It is supplied as a powder to be reconstituted with sterile water for subcutaneous administration in the abdomen.

    The authorization follows degarelix' FDA approval in December 2008.

    In Phase III trials, Firmagnon reportedly reduced the levels of testosterone in more than 96% of patients within three days. Results were close to the immediate effect achieved with surgery, explains Ferring.
    ADNFCR-2184-ID-19038444-ADNFCR



Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »